Before the approval of CD19 CAR-T cells, the 3-year survival rate after the first relapse for adult B-ALL was 11% [1], whereas for pediatric patients the event-free survival did not exceed 50% [2,3]. The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.